Interferon Type I, Recombinant
Research News and Information

Monday, November 23, 2009

Hepatitis C: The role of new interferons in the era of STAT-C.

30 Aug 2009 More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. potent treatment strategies are urgently needed to improve outcomes for such patients. novel interferons and specifically ... Read more...

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

16 Aug 2009 BACKGROUND: Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined ... Read more...

Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.

8 Aug 2009 BACKGROUND: Interferon beta has been approved for the treatment of multiple sclerosis (MS). It is believed that immunomodulatory rather than antiviral activity of interferon beta is responsible for disease amelioration. The impact of interferon beta ... Read more...

Latest indexed articles for 'Interferon Type I, Recombinant'

These are the very latest articles for this heading:

• Immunotherapy for multiple sclerosis: the curious case of interferon beta. 29 Sep 2009
• Hepatitis C: The role of new interferons in the era of STAT-C. 30 Aug 2009
• Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: really safe and effective? 30 Aug 2009
• Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. 16 Aug 2009
• Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. 8 Aug 2009
• Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. 19 Jul 2009
• Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. 7 Jul 2009
• [Effects of human and rat interferons-alpha on the behavior of rats of different ages. Comparative study of the homology of amino acid sequences] 29 Jun 2009
• Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. 27 Jun 2009
• Correlated bivariate continuous and binary outcomes: issues and applications. 13 Jun 2009
• Pharmacotherapy of multiple sclerosis: the PROOF trial. 30 May 2009
• Management of patients co-infected with HBV and HCV. 30 May 2009
• Serine protease inhibitors as anti-hepatitis C virus agents. 30 May 2009
• Treatment of HBV-related cirrhosis. 30 May 2009
• Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. 30 May 2009
• The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. 13 May 2009
• Recombinant interferon-beta therapy and neuromuscular disorders. 11 May 2009
• Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1). 29 Apr 2009
• Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferon. 26 Apr 2009
• Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy. 8 Apr 2009

See a longer list of these articles.

Technical information about 'Interferon Type I, Recombinant'

Definition: A type I interferon with antiviral and antineoplastic activity produced by recombinant DNA technology. It can be a mixture of alpha and beta interferons.

Registry Number: 0

Descriptor UI: D015379

Alternative terms: Interferon Type I, Recombinant; Interferon Beta, Recombinant; Beta, Recombinant Interferon; Recombinant Interferon Beta; Interferon Alfa, Recombinant; Recombinant Interferon Alfa; Interferon Alpha, Recombinant; Alpha, Recombinant Interferon; Recombinant Interferon Alpha;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antineoplastic Agents; Antiviral Agents; Angiogenesis Inhibitors;

Tree Number: D12.644.276.374.440.890.125; D12.644.276.718.500.125; D12.776.467.374.440.890.125; D12.776.467.718.500.125; D12.776.828.200; D23.529.374.440.890.125; D23.529.718.500.125;

History Note: 2000(1989)